Welcome to our dedicated page for Renovorx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on Renovorx stock.
Renovorx Inc (RNXT) pioneers targeted therapeutic delivery systems designed to transform cancer treatment and vascular interventions through its proprietary Trans-Arterial Micro-Perfusion technology. This page serves as the definitive source for verified updates about the clinical-stage innovator’s progress in precision medicine.
Investors and medical professionals will find comprehensive coverage of FDA clearances, clinical trial milestones, and strategic partnerships. Track developments in RNXT’s pipeline including oncology-focused device innovations and evidence-based research validating its Renovocath™ delivery platform.
Key updates include regulatory submissions, peer-reviewed study results, manufacturing collaborations, and financial performance reports. All content is curated to support informed analysis of RNXT’s position in the competitive medical device sector while adhering to strict journalistic standards.
Bookmark this page for streamlined access to essential RNXT developments. Combine our real-time updates with Stock Titan’s financial tools to monitor this innovator in localized therapeutic delivery systems.
RenovoRx (RNXT) announces the initiation of patient enrollment at SCRI Oncology Partners in Nashville for its pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC). The study evaluates the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, comparing intra-arterial gemcitabine delivery via RenovoCath against standard intravenous chemotherapy.
Dr. Meredith Pelster, Associate Director for GI Research at Sarah Cannon Research Institute (SCRI), has been appointed as Principal Investigator. The company expects to complete enrollment in the first half of 2025. SCRI Oncology Partners, part of a network reaching one in five cancer patients across 250+ locations in 24 U.S. states, joins other clinical sites participating in the study.
RenovoRx (Nasdaq: RNXT) has announced an upcoming investor fireside chat scheduled for Tuesday, December 17, 2024, at 4:30 p.m. ET. CEO Shaun Bagai will discuss the company's 2024 achievements and 2025 outlook, focusing on two key areas:
1. The commercialization strategy for the RenovoCath delivery system, including insights from newly appointed Commercial Advisor Richard Stark
2. Updates on the pivotal Phase III TIGeR-PaC clinical trial, which evaluates their proprietary TAMP™ therapy platform for locally advanced pancreatic cancer treatment. The trial combines their RenovoCath delivery system with gemcitabine chemotherapy.
Important 2025 milestones include the anticipated second interim data readout and completion of patient enrollment in the TIGeR-PaC study. The event will include a Q&A session, and a recording will be available on RenovoRx's Investor Relations website.
RenovoRx (NASDAQ: RNXT) has received its first purchase orders for its FDA-cleared RenovoCath® delivery system, with over ten medical institutions initiating the purchase process nationwide. The company estimates an initial target market size of several hundred million dollars in annual sales for RenovoCath, which is powered by their patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.
The device has been successfully used in over 500 clinical trial procedures. RenovoRx is pursuing a direct-to-market commercialization strategy and has expanded its relationship with manufacturing partner Medical Murray to increase production. The company expects to complete patient enrollment and the next interim analysis of its Phase III TIGeR-PaC clinical trial by the end of H1 2025.
RenovoRx (RNXT) announces that Northwell Health Cancer Institute (NHCI) has joined its pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer (LAPC). The trial evaluates RenovoRx's TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, comparing intra-arterial gemcitabine delivery via the FDA-cleared RenovoCath system to standard intravenous chemotherapy. NHCI joins other U.S. clinical sites in the study, which aims to complete enrollment in the first half of 2025.
RenovoRx reported Q3 2024 financial results with $9.6 million in cash as of September 30, sufficient to fund operations through next interim analysis of its Phase III TIGeR-PaC clinical trial and RenovoCath commercialization efforts. The company reported a net loss of $2.5 million, with R&D expenses at $1.7 million and G&A expenses at $1.2 million. RenovoCath, their FDA-cleared delivery system, is advancing towards commercialization with increased production and potential revenue generation in 2025. The Phase III trial for locally advanced pancreatic cancer is progressing towards completion of patient enrollment, expected in first half of 2025.
RenovoRx (Nasdaq: RNXT) announces increased production of its FDA-cleared RenovoCath® delivery system due to high demand from oncologists and interventional radiologists. The company has expanded its relationship with manufacturing partner Medical Murray, issuing a warrant for up to 709,500 shares of RenovoRx common stock as performance incentives. RenovoRx remains committed to its Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), using the TAMP™ therapy platform.
The company is exploring commercial opportunities for RenovoCath as a standalone device, with plans to launch during 2025. RenovoRx has promoted Robert Strasser to Vice President of R&D and Operations to support these efforts. The company maintains sufficient cash to fund both the next interim read-out on TIGeR-PaC and RenovoCath go-to-market activities.
RenovoRx (RNXT) announced that Dr. Ripal Gandhi will present at the Symposium on Clinical Interventional Oncology, highlighting the company's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for treating locally advanced pancreatic cancer (LAPC). The presentation will focus on:
1. Clinical challenges of standard LAPC treatments
2. TAMP as a potential targeted oncology option
3. Status of the ongoing Phase III TIGeR-PaC study
4. Recent publication in The Oncologist® on early-stage clinical data
The presentation will take place on September 21, 2024, at 9:30am ET in Miami Beach, Florida. Dr. Gandhi, a principal investigator for RenovoRx's TIGeR-PaC trial since 2018, will discuss how TAMP may offer LAPC patients an alternative to systemic chemotherapy, which often has effectiveness and severe side effects.
RenovoRx (Nasdaq: RNXT), a clinical-stage biopharmaceutical company, announced that CEO Shaun Bagai will present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 at 7:00 a.m. ET in New York City. Bagai will discuss:
- Progress on the pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer (LAPC) using their proprietary TAMP™ therapy platform
- New commercial business development opportunities for their FDA-cleared RenovoCath® delivery system
The company recently appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024. A webcast of the presentation will be available, and one-on-one investor meetings can be scheduled through H.C. Wainwright or KCSA Strategic Communications.
RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform. This approach aims to deliver gemcitabine chemotherapy directly to the tumor site, potentially overcoming the challenge of drug penetration through the tumor's protective scar tissue.
The trial compares TAMP therapy to standard intravenous chemotherapy. UNMC, which joined the study in June 2024, is expected to help drive enrollment to completion by next year. The TIGeR-PaC study is currently enrolling unresectable LAPC patients across multiple US sites, reflecting RenovoRx's commitment to improving outcomes for patients with difficult-to-treat pancreatic cancer.
RenovoRx (Nasdaq: RNXT) announced the publication of positive early-stage clinical data for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform in The Oncologist. The study focused on treating Locally Advanced Pancreatic Cancer (LAPC) using TAMP to deliver gemcitabine. Key findings include:
1. Overall Survival (OS) of 27.1 months for LAPC patients with prior radiation treated with TAMP-delivered chemotherapy.
2. Median OS of 12.6 months for all 35 evaluable LAPC patients.
3. TAMP is currently being evaluated in a Phase III clinical trial for LAPC treatment.
The study suggests TAMP could potentially offer a safer, more effective treatment option for LAPC compared to standard systemic chemotherapy, with fewer side effects.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
